J&J(JNJ) - 2026 Q1 - Earnings Call Presentation

Financial Performance - Worldwide sales reached $24.1 billion in Q1 2026, representing a 9.9% reported growth and 6.4% operational growth[36][37] - Innovative Medicine segment achieved 7.4% operational sales growth, driven by strong performance in Oncology and Neuroscience[20][39] - MedTech segment delivered 4.6% operational sales growth, supported by commercial execution and innovation across its platforms[31][43] - Adjusted net earnings were $6.6 billion, with adjusted diluted EPS of $2.70 for the first quarter of 2026[38][45] Strategic Outlook and Guidance - The company increased its 2026 operational sales guidance midpoint to 6.4%, with a projected range of $99.7 billion to $100.7 billion[51] - Adjusted operational EPS guidance midpoint for 2026 was raised to 5.7%, reflecting a range of $11.30 to $11.50[51] - Capital allocation priorities remain focused on organic business needs, competitive dividends, share repurchases, and strategic M&A, with $3.5 billion invested in R&D during Q1 2026[49] Operational Highlights - The launch of ICOTYDE for plaque psoriasis treatment represents a key milestone in the Immunology portfolio, offering a new systemic treatment option[23][27] - STELARA performance impacted operational results by approximately (920) basis points due to biosimilar competition and market dynamics[22][39] - MedTech growth was bolstered by double-digit performance in the Abiomed and Shockwave portfolios, alongside strong adoption of new product launches[43]